Vimgreen Pharma Completes Enrollment in Phase 2 Trial Of VG081821AC

Vimgreen Pharma Completes Enrollment in Phase 2 Trial Of VG081821AC

By, Admin 20 August 2024

Vimgreen Pharma completes enrollment in phase 2 trial of VG081821AC to treat Parkinson’s disease

Overview

Vimgreen Pharmaceuticals, a science-driven pharmaceutical company focused on the modulation of adenosine signalling, announced the completion of enrollment of its phase 2 clinical trial of VG081821AC, a novel adenosine A2A receptor (A2AR) antagonist that also functions as an inverse A2AR agonist, for the treatment of early-to-mid stage Parkinson’s disease. A total of 150 participants have been enrolled and randomized into one of three cohorts, a high-dose VG081821 group, a low-dose VG081821 group, and a placebo group at a ratio of 1:1:1.

Trial for VG081821

  • The 12-week phase 2 trial is a multicenter, randomized, placebo-controlled, double-blind study to investigate the safety and efficacy of VG081821 as monotherapy in early-to-mid stage PD patients. 
  • The primary endpoint was the difference of change from baseline in movement disorder society-unified Parkinson’s disease rating scale (MDS-UPDRS) part III (motor symptoms) score between VG081821 and placebo over the 12 weeks of administration.

Current Parkinson’s Disease Therapies

  • For PD patients, current therapies are mainly dependent on dopamine replacement strategies with L-Dopa (top choice), dopamine agonists, MAO-B inhibitors and COMT inhibitors. 
  • These medicines either increase dopamine levels or mimic dopamine function. 
  • However, despite L-Dopa’s efficacy in reducing the motor symptoms of PD, the onset of motor complications (wearing-off, ON–OFF, dyskinesia) is almost inevitable with long-term treatment. 
  • It is a well-known limit of the dopamine replacement therapy. In addition, the current therapies for PD are only symptomatic treatments. 
  • These therapies are unable to slow down the progression of PD.

VG081821: an A2AR Antagonist

  • As an A2AR antagonist, which works non-dopaminergically, VG081821 has the potential to avoid, decrease or delay motor complications (wearing-off, ON–OFF, dyskinesia) if used early. 
  • What’s special about VG081821 is that it is not only a highly potent A2A antagonist, but also a highly potent A2A receptor inverse agonist.
  • More than a classical A2A antagonist, VG081821 may have extra therapeutic effect and greater efficacy on motor dysfunction in PD. 
  • Furthermore, VG081821 may provide not only symptomatic benefits, but also disease modifying benefits. 
  • VG081821 is expected to bring better treatment options and clinical benefits for PD patients.

Words frim CEO: Vimgreen

  • In most previous trials of A2A antagonists for the treatment of Parkinson’s disease, A2A antagonists were used as an add-on treatment to alleviate off episodes in combination with L-Dopa for advanced PD patients. Although it has led to the approval of Istradefylline in US and Japan, it is not the best use of A2A antagonists for PD treatment,” stated Sanxing Sun, president and chief executive officer of Vimgreen.
  • VG081821 is to be used as monotherapy for improving movements in early-to-mid stage of PD. Later on, as the disease progresses, it can be used in combination with low doses of L-Dopa. This L-dopa sparing effect may minimize the problem of L-Dopa and prolong the quality of life of PD patients.”

It is known that A2AR gene expression in human peripheral blood mononuclear cells (PBMCs) are higher for PD patients. In the current phase 2 trial of VG081821, the A2AR gene expression levels in PBMCs are to be analyzed. The potential correlation between drug efficacy and A2AR expression level may make VG081821 a precision medicine.

Phase 2 completion- The phase 2 trial is to be completed in November.

About VG081821AC/VG081821

  • VG081821AC/VG081821 is a potent, selective antagonist of adenosine A2A receptor (A2AR) developed by Vimgreen. 
  • Adenosine A2A receptors are distributed across basal ganglia, in particular in the striatum, and are believed to be involved in the regulation of motor functions. 
  • This makes A2AR an attractive non-dopaminergic target to treat the disease. 
  • VG081821 is an innovative A2AR antagonist that is not only a highly potent A2A antagonist, but also a highly potent A2A receptor inverse agonist. 
  • It is expected to bring better treatment options and clinical benefits for PD patients.

About Vimgreen

  • Vimgreen is a science-driven pharmaceutical company located in the beautiful city of Hangzhou, China. 
  • At Vimgreen, the research programmes are focused on the modulation of adenosine signalling.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!